Comparative Pharmacology
Head-to-head clinical analysis: MYTELASE versus REGONOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTELASE versus REGONOL.
MYTELASE vs REGONOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Regorafenib is a multikinase inhibitor that targets various receptor tyrosine kinases involved in angiogenesis, oncogenesis, and tumor microenvironment, including VEGFR1-3, TIE2, PDGFR-β, FGFR1, KIT, RET, RAF-1, and BRAF.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
Intravenous: 400 mg every 12 hours for 60 doses. Maintenance: 400 mg twice daily for 180 days (6 months).
None Documented
None Documented
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Terminal half-life of 2–4 hours; clinically relevant for dosing every 6–8 hours in renal impairment.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Approximately 70% renal (unchanged) and 30% biliary/fecal as glucuronide conjugates.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor